ENGN Similar Chart Price Prediction
The price of ENGN is predicted to go up -8.08%, based on the high correlation periods with DIOD. The similarity of these two price pattern on the periods is 95.65%.
ENGN
DIOD
Down: -8.08%Similarity: 95.65%
ENGN Revenue Forecast
ENGN EPS Forecast
ENGN FAQs
What is bull’s view on ENGN?
What is bear's view on ENGN?
What is ENGN eps forecast for next quarter？
ENGN Analyst's Forecast
Colin Bristow
UBS
Strong Buy → Hold
2025-02-14
Price Target
$34 → $7
Upside
+6.22%
UBS downgraded enGene (ENGN) to Neutral from Buy with a price target of $7, down from $34, after assuming coverage of the name. enGene's lead program, detalimogene, previously demonstrated lower efficacy in BCG-unresponsive high risk non-muscle invasive bladder cancer vs. competitor CG Oncology's (CGON) creto and Johnson & Johnson's (JNJ) TAR-200 in a Phase 2 pivotal trial, and while the protocol change could improve deta's efficacy, the efficacy would likely be similar to creto's BOND-003 data, the analyst tells investors in a research note. The firm sees data updates in the second half of 2025 as largely incremental with limited upside.
Sean McCutcheon
Raymond James
Buy
2024-11-27
Price Target
$23
Upside
+167.13%
Silvan Tuerkcan
JMP Securities
Buy
2024-11-18
Price Target
$18
Upside
+139.36%
